Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: Current status and future development

Critical Reviews in Oncology/Hematology

Volumn 68, Issue 3, 2008, Pages 222-232

  Guida, Cesare ^a   Maione, Paolo ^a   Rossi, Antonio ^a   Bareschino, Marianna ^a   Schettino, Clorinda ^a   Barzaghi, Domenico ^a   Elmo, Massimo ^a   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Angiogenesis inhibitors; Combined chemo radiotherapy; EGFR inhibitors; Locally advanced NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; VANDETANIB; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGITIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RESPIRATORY TRACT DISEASE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TRACHEOESOPHAGEAL FISTULA; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS;

EID: 54449087649     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.05.007     Document Type: Review

References (66)

1. Rosell R. The integration of newer agents into neoadjuvant therapy. Semin Oncol 25 Suppl. 8 (1998) 24-27
2. Gandara D.R., Lara Jr. P.N., Goldberg Z., Roberts P., and Lau D.H. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs 12 Suppl. 1 (2001) S5-S9
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311 (1995) 899-909
4. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., and Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
5. Sause W., Kolesar P., Taylor IV S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
6. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326 (1992) 524-530
7. Jeremic B., Shibamoto Y., Acimovic L., and Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14 (1996) 1065-1070
8. Curran Jr. W.J., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22 (2003) 621
9. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
10. Movsas B., Scott C., Curran W., Byhardt R., and Langer C. A Quality-Adjusted Time Without Symptoms or Toxicity (QTWiST) analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 20 (2001) 313a
11. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francaisde Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 25 (2005) 5910-5917
12. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
13. Belderbos J., Uitterhoeve L., van Zandwijk N., et al., EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43 1 (2007) 114-121
14. Rowell N.P., and O'rourke N.P. Concurrent chemoradiotherapy in non-small-cell lung cancer. Cochrane Database Syst Rev 4 (2004) CD002140
15. Movsas V., Moughan J., Komaki R., et al. Radiotherapy (RT) Patterns of Care Study (PCS) in lung carcinoma. J Clin Oncol 21 (2003) 4553-4559
16. Vokes E.E., Herndon J.E., Crawford J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007) 1698-1704
17. Choy H., Curran W.J., Scott C.B., et al. Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC) (Abstract). Proc Am Soc Clin Oncol 21 (2002) 291°
18. Vokes E.E., Herndon II J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20 (2002) 4191-4198
19. Huber R.M., Schmidt M., Flentje M., et al. Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB). Proc Am Soc Clin Oncol 22 (2003) [abstract #622]
20. Huang E., Zhongxing L., Guerrero T.M., et al. Comparison of outcomes for patients with unresectable, Locally advanced non-small-cell lung cancer treated with Induction chemotherapy followed by concurrent Chemoradiation vs. Concurrent chemoradiation alone. Int J Radiation Oncology Biol Phys 68/3 (2007) 779-785
21. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer. J Natl Cancer Institute 87/3 (1995) 198-205
22. Gandara D., Chansky K., Albain K.S., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-smallcell lung cancer: phase-II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
23. Hanna H., Neubauer M., Ansari R., et al. Phase III trial of cisplatin plus etoposide plus concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol 25/18S (2007) 7512
24. Kim S., Kim M., Choi E., et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): Randomized phase III trial. J Clin Oncol 25/18S (2007) 7528
25. Vokes E.E., Crawford J., Bogart J., Socinski M.A., Clamon G., and Green M.R. Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer. Clin Cancer Res 11 (2005) 5045s-5050s
26. Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non small cell lung cancer. New Engl J Med 353 (2005) 123-132
27. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med 355 (2006) 2542-2550
28. Manegold C., von Pawel J., Zatloukal P., et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25/18S (2007) LBA7514
29. Douillard J.Y., Hirsh E., Mok V., et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). J Thorac Oncol 2/8 Suppl. 4 (2007) S305
30. Raymond R., Faivre S., and Armand J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl. 1 (2000) 15-23
31. Dent P., Reardon D., Park J., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10 (1999) 2493-2506
32. Akimoto T., Hunter N.R., Buchmiller L., Masou K., Ang K.K., and Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 (1999) 437-443
33. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
34. Bianco C., Tortora G., Bianco R., et al. Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839 (Iressa). Clin Cancer Res 8 (2002) 3250-3258
35. Rischin D., Burmeister B., Mitchell P., et al. Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. J Clin Oncol 22/14S (2004) 7077
36. Ready N., Janne P., Herndon J., et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer: a CALGB stratified phase II trial. J Clin Oncol 24 (2006) 375s [abstract 7046]
37. Hoffman P.C., Mauer A.M., Haraf D.C., Lester E.P., Szeto L.L., and Vokes E.E. A phase I study of erlotinib in combination with chemoradiation for unresectable, locally advanced non-small cell lung cancer. J Clin Oncol 23/16S (2005) 648s [abstr. 7113]
38. Kelly K., Chansky K., Gaspar L.E., et al. Updated analysis of SWOG 0023: a randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 25 (2007) 388s [abstr. 7513]
39. Werner-Wasik M., Swan S., Curran W., et al. A phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small cell lung cancer: an interim overall toxicity report of the RTOG 0324 trial. J Clin Oncol 23/16S (2005) 654s [abstr. 7135]
40. Bogart J.A., and Govindan R. A randomized phase II study radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. Clin Lung Cancer 7 (2006) 285-287
41. Steinauer K.K., Gibbs I., Ning S., French J.N., Armstrong J., and Knox S.J. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Rad Oncol Biol Phys 48 (2000) 325-328
42. Teicher B.A., Depuis N.P., Kusumoto T., et al. Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 2 (1995) 269-276
43. Food and Drug Administration: Important drug warning regarding Avastin (bevacizumab). http://www.fda.gov/medwatch/safety/2007/Avastin_DHCP_TEF_Final_April2007 .pdf.
44. Keiko S., Komaki R., Wenjuan W., et al. Targeted therapy against VEGF and EGF signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer. Proceedings of the 46th annual meeting of american society of therapeutic radiology and oncology. October 3-7 (2004) [Abst #35]
45. Gridelli C., Maione P., Del Gaizo F., et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12/2 (2007) 191-200
46. Atagi S., Kawahara M., Ogawara M., et al. Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 30 (2000) 59-64
47. D'Angelillo R.M., Trodella L., Ramella S., et al. Neoadjuvant chemoradiotherapy followed by surgery in elderly patients with locally advanced Non-Small Cell lung Cancer: analysis of feasibility, toxicity and factors predicting surgical resection and survival. Proc Am Soc Clin Oncol 23 (2004) 654
48. Atagi S., Kawahara M., Tamura T., et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 35 (2005) 195-201
49. Movsas B., Scott C., Sause W., et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 45 (1999) 1143-1149
50. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48 (2000) 1475-1482
51. Langer C., Scott C., Byhardt R., et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC. Lung Cancer 29 Suppl. 1 (2000) 119
52. Langer C.J., Hsu C., Curran W.J., et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 21 (2002) 299a
53. Schild S.E., Stella P.J., Geyer S.M., et al., North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21 (2003) 3201-3206
54. Perrone F., Gallo C., and Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (2002) 1029-1031
55. Schild S.E., and Bogart J.A. Innovations in the radiotherapy of non-small cell lung cancer. J Thor Oncol 1/1 (2006) 85-90
56. Schild S.E., Stella P.J., Geyer S.M., et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54 (2002) 370-378
57. Komaki R., and Seiferheld W. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 48 (2000) 113
58. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., and Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial: CHART Steering committee. Radiother Oncol 52 (1999) 137-148
59. Schild S.E., Wong W.W., Vora S.A., et al. The long-term results of a pilot study of three times a day radiotherapy and escalating dosesof daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 62 (2006) 1432-1437
60. Socinski M.A., Morris D.E., Halle J.S., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
61. Sura S., Gupta V., Yorke E., Jackson A., Amols H., and Rosenzweig K.E. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87 (2008) 17-23
62. Chang J.Y., Dong L., Liu H., et al. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol 3 (2008) 177-186
63. Timmerman R., Papiez L., McGarry R., et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124 (2003) 1946-1955
64. Onishi H., Araki T., Shirato H., et al. Stereotactic hypofractionated high-dose irradiation for stage I non small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101 (2004) 1623-1631
65. Kepka L., Danilova V., Saghatelyan T., et al. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer 56/2 (2007) 235-245
66. Kong F., West B., Bonner J., Choy H., Gaspar L.E., and Komaki R. Patterns of practice in radiation therapy for non-small cell lung cancer among members of American Society of Therapeutic Radiology and Oncology. J Clin Oncol 25/18S (2007) 7693